Expression of the B-Myb transcription factor is directed by an E2F-dependent transcriptional mechanism to late G1 and S phases of the cell cycle, where its transactivation properties are enhanced post-translationally by cyclin A/Cdk2-mediated phosphorylation. Other experiments have shown that removal of the B-Myb Cterminus constitutively activates both transactivation and DNA-binding activities, suggesting that autoregulation by this inhibitory domain is counteracted by phosphorylation. We report here on further experiments to examine this hypothesis. The importance of this modi®cation was ®rst emphasized by showing that cotransfected dominant-negative Cdk2 (Cdk2DN) substantially reduced B-Myb transactivation activity. We then attempted to map the autoregulatory domain by analysing a series of progressively deleted C-terminal B-Myb mutants. Removal of just 29 C-terminal aa increased transactivation appreciably, however, maximal activity required removal of 143 amino acids (as in BMyb+561). Enhanced B-Myb+561 function correlated with the acquisition of DNA binding activity to a single Myb binding site (MBS) oligonucleotide as determined by bandshift assays, however, further assays showed that even wt B-Myb could bind a DNA fragment containing three MBS. Although transactivation by B-Myb was severely dependent on hyperphosphorylation, neither inhibiting this activity by co-transfecting Cdk2DN nor augmenting it with cyclin A resulted in signi®cant eects on DNA-binding. We also found that B-Myb could synergize with the CBP coactivator and that this cooperativity was cyclin A/Cdk2-dependent. Despite this, the physical association between these proteins was not in¯uenced by the B-Myb phosphorylation status. We discuss these ®ndings in relation to the autoregulation of B-Myb by the C-terminal domain. Oncogene (2001) 20, 3376 ± 3386.
Introduction
The mammalian cell cycle is temporally controlled by the cyclins and their associated enzymatic subunits, the cyclin-dependent kinases (Cdks). A critical function of the G 1 cyclin/Cdk complexes, cyclin D/Cdk4 or Cdk6 and cyclin E/Cdk2, is phosphorylation of the retinoblastoma protein, pRb, and the related p107 and p130 proteins (reviewed in Weinberg, 1995) . This results in disruption of transcriptionally repressive complexes with the E2F transcription factor, leading to activation of gene expression essential for entry into and progress through S phase. Our previous work has demonstrated that one of the targets of this regulatory mechanism is B-Myb (Lam et al., 1994 (Lam et al., , 1995 Lam and Watson, 1993) , a gene related to the c-Myb proto-oncogene and A-Myb. In contrast to the restricted tissue tropism exhibited by c-Myb and A-Myb expression, B-Myb appears to be ubiquitously expressed in proliferating somatic cells (Golay et al., 1991; Kamano et al., 1995; Lam et al., 1992; Nomura et al., 1988; Reiss et al., 1991) and throughout mouse embryogenesis (Sitzmann et al., 1996) . Gene knockout experiments have revealed that the B-Myb protein plays a critical role at a very early developmental stage (Tanaka et al., 1999) ; homozygous B-Myb-de®cient mutants died around E4.5 ± E6.5, and a requirement for B-Myb in inner cell mass formation was indicated by the severely impaired proliferation of in vitro cultures of mutant blastocysts. These studies are all consistent with a role for B-Myb in cell proliferation as suggested by earlier reports that B-Myb antisense oligonucleotides or RNA prevent growth of haemopoietic and ®broblast cell lines (Arsura et al., 1992; Sala and Calabretta, 1992) and that B-Myb overexpression overcomes growth arrest associated with terminal dierentiation of monocytic cells (Bies et al., 1996) .
The Myb genes encode transcription factors which display characteristic regions of homology. The most homologous region is the N-terminal DNA-binding domain, consisting of three imperfect repeats of 51 ± 52 amino acids (aa), which recognizes the distinctive Myb DNA binding sequence (MBS), CNGTTR (Biedenkapp et al., 1988) . The C-termini of the Myb proteins contain a further extensive region of homology referred to as the conserved region (CR). Although CR function is incompletely understood, Cterminal deletions within c-Myb increase DNAbinding, transactivation and transformation activities (Dubendor et al., 1992; Hu et al., 1991; Kalkbrenner et al., 1990; Ramsay et al., 1991) , suggesting that this region contains a negative-regulatory domain. Several distinct c-Myb motifs contribute to negative regulation, including a leucine zipper-like structure (Kanei-Ishii et al., 1992) and the EVES motif, which participates in intramolecular interactions with the DNA-binding domain (Dash et al., 1996) . C-terminal truncations of B-Myb also increase activity on MBS-regulated promoters (Lane et al., 1997; ; although this points to similarities with c-Myb regulation, neither the leucine zipper nor the EVES motif are conserved in B-Myb. It is also notable that whereas binding of full-length c-Myb to a single MBS could readily be detected in electrophoretic mobility shift assays (EMSA), in vitro DNA-binding by B-Myb could not be demonstrated unless the C-terminus was extensively truncated (Howe et al., 1990; Watson et al., 1993) . B-Myb is generally a weaker transactivator than c-Myb, and this activity displays some tissue speci®city (Tashiro et al., 1995) . Altogether, these ®ndings imply that BMyb transcriptional activity is more strictly regulated than c-Myb.
Transcriptional regulation by E2F directs maximal B-Myb protein expression to S phase, indicating that it has a critical function at this stage of the cell cycle, however, the target genes have yet to be identi®ed. Signi®cantly, B-Myb undergoes a characteristic electrophoretic mobility shift in S phase, indicative of phosphorylation (Robinson et al., 1996) . Consistent with the timing of this modi®ca-tion, we found that B-Myb was a substrate for the S phase-speci®c cyclin A/Cdk2, but was not ostensibly modi®ed by cyclin E/Cdk2 or cyclin D1/ Cdk4. These ®ndings suggested that B-Myb function is post-translationally regulated during the cell cycle, and subsequently a number of laboratories reported that ectopic expression of cyclin A enhanced B-Myb transactivation activity (Ansieau et al., 1997; Lane et al., 1997; Sala et al., 1997; . Several cyclin A/Cdk2 phosphorylation sites have now been mapped in the C-terminal half of BMyb (Bartsch et al., 1999; Johnson et al., 1999; Saville and Watson, 1998) . Mutation of these sites impairs the response of B-Myb to cyclin A, however, the mechanism by which phosphorylation regulates transactivation is as yet unknown. As the phosphorylation sites cluster within a region associated with negative-regulation of B-Myb, we further characterized this autoregulatory domain and investigated whether B-Myb hyperphosphorylation aects interactions with DNA and the CBP transcriptional coactivator.
Results

Inhibition of B-Myb hyperphosphorylation is associated with reduced transactivation activity
We have shown previously that B-Myb transactivation activity is enhanced in cells co-transfected with a cyclin A expression plasmid, and that this eect could be abolished by a dominant-negative Cdk2, Cdk2DN (Lane et al., 1997) . This and other studies (Sala et al., 1997; Ansieau et al., 1997) have clearly indicated that B-Myb function is stimulated upon phosphorylation by cyclin A/Cdk2. To investigate further the dependence of B-Myb function on cyclin A/Cdk2 modi®cation, the eects of inhibiting this activity by titrating increasing amounts of a Cdk2DN expression plasmid were tested. B-Myb transactivation activity was assessed in co-transfected U-2 OS cells using the pT81luc 36A reporter, whose promoter is regulated by three high anity MBS (the A site) from the chicken mim-1 gene (Ness et al., 1989) . Signi®cant inhibition of B-Myb transactivation function was observed even at very low Cdk2DN plasmid inputs (0.03 mg), although maximal inhibition was achieved at an input of 1 mg (Figure 1a ). Even at the latter Cdk2DN input, B-Myb still retained a low level of transactivation activity (about threefold), suggesting either that the unphosphorylated protein had some inherent activity or that transfected Cdk2DN was unable to block completely B-Myb phosphorylation (which possibly is mediated by distinct kinases). It is notable that inhibition of B-Myb transactivation, particularly at low Cdk2DN input, was associated with increased expression of B-Myb protein ( Figure  1b) , consistent with recent evidence that phosphorylation of B-Myb at cyclin A/Cdk2 sites leads to enhanced degradation of the protein (Charrasse et al., 2000) .
Mapping the C-terminal B-Myb negative-regulatory domain
We and others have found previously that truncation of the B-Myb C-terminus enhances transactivation activity and renders the protein relatively insensitive to further activation by cyclin A (Lane et al., 1997; , suggesting that this region of the protein contains a phosphorylation-regulatable domain. To try to de®ne this domain, we ®rst constructed a panel of progressively truncated C-terminal B-Myb mutants. The truncation endpoints are illustrated in Figure 2 with reference to the B-Myb domains and the 12 cyclin A/Cdk2 phosphorylation sites which have been mapped to date. Expression plasmids encoding wild-type (wt) B-Myb and the truncated variants were then co-transfected into U-2 OS cells with the pT81luc 36A reporter, together with either a control vector or expression vectors encoding cyclin A and Cdk2. These assays showed that wt B-Myb moderately transactivated (15-fold) the reporter in the absence of cyclin A/ Cdk2, however, each of the C-terminally truncated mutants was considerably more transcriptionally active (Figure 2c ). Thus, deletion of just 29 aa generated a protein (B-Myb+675) which activated the reporter 100-fold, whilst progressively deleted proteins displayed even greater activity (Figure 2c ). The most active protein in the absence of exogenous cyclin A/Cdk2 was found to be B-Myb+561, which notably contains the entire CR previously implicated in transactivation (Nakagoshi et al., 1993) .
As expected, cyclin A/Cdk2 signi®cantly enhanced transactivation by wt B-Myb (Figure 2c ), moreover, it was apparent that virtually all the truncated mutants were stimulated to an extent under these conditions. The single exception to this was the most extensively truncated mutant, B-Myb+394, in which all but two of the 12 identi®ed phosphorylation sites have been eliminated. It is clear when the fold activation by cyclin A/Cdk2 is considered (Figure 2d ), that wt B-Myb is more responsive to cyclinA/Cdk2 than any of the mutants. Thus, cyclin A/Cdk2 stimulated wt B-Myb activity 13.5-fold, whereas the most active mutant, BMyb+561, was stimulated only twofold. Pertinently, the least truncated mutant, B-Myb+675, was stimulated to a greater extent (8.5-fold) than any of the other mutants (Figure 2d ), suggesting that this mutant retains partial function of a C-terminal negative regulatory domain. Reporter activity was stimulated 4.7-fold in control cells which received no exogenous B-Myb; although this raises the possibility that some of the eects observed with cyclin A/Cdk2 were independent of B-Myb, it should be noted that reporter activity was not stimulated in cells transfected with BMyb+394. This suggests that stimulation of the reporter in control cells was mediated by endogenous (Bartsch et al., 1999; Johnson et al., 1999; Saville and Watson, 1998) Overall, these results indicate that the extreme Cterminus of B-Myb (i.e. downstream of +664) is required for full autoregulation of B-Myb transactivation activity, and that negative regulation by this region can be overcome, at least in part, by cyclin Amediated phosphorylation. The results also point to certain other eects of phosphorylation. For example, mutants +664, +625, +608 and +590 were all stimulated approximately fourfold by cyclin A/Cdk2, whereas the most active mutant, B-Myb+561, was enhanced only twofold ( Figure 2d ). This suggests that sequences lying between +561 and +590 also contribute to a cyclin A-responsive domain.
DNA-binding activities of C-terminally truncated B-Myb proteins
We have shown previously that C-terminal truncation of B-Myb unmasks latent DNA-binding activity , therefore, we investigated whether this could account for the increase in transactivation activity obtained with the mutant proteins. So that DNA-binding and transactivation activities could be readily equated, U-2 OS cells were co-transfected with wt and mutant B-Myb expression plasmids together with the pT81luc 36A reporter, and EMSA and reporter assays were then carried out on the same extracts. Using a 32 P-labelled oligonucleotide containing a single mim-1 A site as a probe in EMSA, a common array of bands was evident with all B-Myb transfected extracts ( Figure 3a) ; clearly these bandshifts were B-Myb-speci®c as they were absent from the vector-transfected control. A unique lower-mobility bandshift was obtained only when B-Myb was truncated to +561, and further truncation resulted in successive increases in electrophoretic mobility of this band ( Figure 3a ). These ®ndings indicate that the uppermost bands seen with B-Myb+561 and the more truncated mutants represents binding by the intact mutant proteins (e.g. aa 1 ± 561), whilst the common array of B-Myb-speci®c bandshifts represents Nterminal protein fragments. Indeed, the Western blot of these extracts revealed a common band which approximately comigrated with B-Myb+444, and other truncated forms were also apparent at lower intensity ( Figure 3b ). The ready generation of these fragments most likely explains previous reports of BMyb DNA-binding activity in transfected cell extracts (Raschella et al., 1995; Sala et al., 1999) . It is notable that the appearance of DNA-binding activity in this assay upon truncation to +561 is correlated with a distinct upward shift in transactivation activity ( Figure  3c ).
The absence of DNA-binding activity seen with wt B-Myb and the +675 to +590 truncated derivatives is anomalous with respect to their transactivation activities (Figure 3c ), particularly as previous experiments indicated that transactivation of pT81luc 36A by wt B-Myb is largely dependent upon the three MBS present in this promoter (Lane et al., 1997) . We therefore tested whether additional bandshifts could be detected using a pT81luc 36A DNA fragment containing the three mim-1 A sites. These experiments were done entirely at 48C to minimize proteolytic cleavage of B-Myb. Using this probe, a major bandshift was obtained with wt B-Myb and similar bandshifts with increasing mobility were seen with the truncated variants (Figure 4a ). Using antibodies directed against the B-Myb C-terminus (aa 561 ± 704), it was con®rmed that the uppermost wt B-Myb and BMyb+590 bands resulted from DNA-binding by proteins that contained sequences downstream of the +561 endpoint (Figure 4b ).
It is notable that additional lower-mobility bandshifts were obtained with B-Myb+561 and the more extensively truncated proteins (Figure 4a ). This is most clearly seen with B-Myb+394, where the two upper bandshifts presumably represent occupation of two and three MBS in the probe, respectively. The combined results of EMSA indicate that while fulllength B-Myb is able to interact with a DNA fragment containing three MBS, it has relatively low binding anity compared to extensively C-terminally truncated derivatives. The acquisition of higher anity DNA-binding by truncation to +561 correlates with a pronounced upward shift in transactivation activity (Figure 3c ).
Cyclin A-mediated regulation of B-Myb transactivation activity cannot be accounted for by effects on DNA-binding affinity As B-Myb C-terminal sequences downstream of +561 clearly reduce DNA-binding anity, we investigated whether cyclin A/Cdk2 phosphorylation may overcome this negative in¯uence. Extracts were prepared from U-2 OS cells co-transfected with combinations of expression vectors encoding wt B-Myb, B-Myb+590 and B-Myb+561 together with cyclin A or Cdk2DN. All transfections also contained the pT81luc 36A reporter. Using the pT81luc 36A DNA fragment as a probe in EMSA, it was found that cyclin A cotransfection did not lead to a discernible increase in DNA-binding anity of wt B-Myb (Figure 5a ), despite resulting in a fourfold increase in transactivation activity (Figure 5c ). Conversely, B-Myb DNA-binding activity was only diminished slightly by co-transfection of Cdk2DN (Figure 5a ), although this resulted in the complete loss of B-Myb hyperphosphorylation ( Figure  5b ) and an eightfold reduction of B-Myb transactivation activity (Figure 5c ). Indeed, the slight eect on DNA-binding noted with this extract was likely due to a small decrease in B-Myb expression levels resulting from the high Cdk2DN input used to minimize B-Myb phosphorylation (Figure 5b ). DNA-binding activity in cells transfected with the truncated B-Myb+590 and B-Myb+561 proteins was noticeably increased by cyclin A co-transfection, but this was associated with some increase in protein levels ( Figure 5 ), suggesting that B-Myb phosphorylation was not directly responsible for this eect. Consistent with this, co-transfection of Cdk2DN had no eect upon the DNA-binding activities of the truncated B-Myb proteins. Similar EMSA performed with the single mim-1 A site MBS oligonucleotide (data not shown) failed to reveal any DNA-binding activity when wt B-Myb or B-Myb+590 were transfected with cyclin A, even when Cdk2 was also incorporated. It is concluded that while regulation by cyclin A/Cdk2 through the C-terminal domain of BMyb profoundly aects transactivation function, this does not re¯ect changes in B-Myb DNA-binding anity. (Dai et al., 1996; Facchinetti et al., 1997; Oelgeschlager et al., 1996) . It is known that phosphorylation regulates the interaction between certain other transcription factors and CBP; for example, protein kinase A phosphorylation of CREB is required for the interaction with CBP (Chrivia et al., 1993) , while cyclin E/Cdk2 stimulates E2F-5 transcriptional activity by facilitating its binding to CBP (Morris et al., 2000) . We investigated therefore whether synergism with CBP could account for the enhancement of B-Myb function by cyclin A/Cdk2. The relative ability of CBP to synergize with B-Myb and c-Myb was tested in Saos-2 cells, which have often been used for this type of study. It should be noted that B-Myb is a weaker transactivator in these cells than in U-2 OS cells. c-Myb was found to activate the pT81luc 36A reporter ®vefold in the absence of transfected CBP, moreover, this activity was stimulated a further fourfold by co-transfection of 5 mg of the CBP expression plasmid (Figure 6 ). Although B-Myb was only weakly active (twofold) in the absence of transfected CBP, co-transfection of CBP stimulated activity a further threefold (Figure 6 ). In a further series of experiments, we examined whether cyclin A or Cdk2DN would aect the synergy between B-Myb and CBP ( Figure 7a ). As expected, cyclin A enhanced BMyb activity and, signi®cantly, this activity was further stimulated by CBP co-transfection. In contrast, Cdk2DN completely abrogated the ability of CBP to synergize with B-Myb (Figure 7a ). It is noted that CBP did not alter the expression levels of transfected B-Myb Figure 5 The B-Myb phosphorylation status has no signi®cant eect on DNA binding anity. U-2 OS cells were transfected with the pT81luc 36A reporter together with plasmids comprising the empty pcDNA3 expression vector (Con) or pcDNA3 expressing wt B-Myb (wt) or the C-terminally truncated derivatives B-Myb+590 or B-Myb+561. As indicated, these cells were also co-transfected with the empty pCMV expression vector (Vector) or pCMV expressing cyclin A (cycA) or Cdk2DN. Cell extracts were made and subjected to reporter gene assays, Western blotting and EMSA. (a) EMSA was performed with 10 mg of each extract using a (Figure 7b ). These ®ndings show that at a functional level the B-Myb/CBP interaction is in¯uenced by phosphorylation. It was apparent, however, that transactivation by the transcriptionally activated BMyb+561 protein was not further enhanced by CBP co-transfection (Figure 7a ), nor was this activity signi®cantly in¯uenced by cyclin A/Cdk2.
To investigate whether hyperphosphorylation of BMyb stimulated binding to CBP, immunoprecipitates selected with a CBP monoclonal antibody from transfected cell lysates were probed for B-Myb by Western blotting. This study indicated that B-Myb could be pulled down by the CBP antibody, but not by an irrelevant monoclonal antibody (Figure 8 ). This interaction was not aected by co-transfected cyclin A or Cdk2DN, indicating that the in vivo interaction between B-Myb and CBP was not aected by the phosphorylation status. It is likely therefore that the failure of B-Myb to synergize with CBP in Cdk2DN-transfected cells re¯ects the inherent inability of hypophosphorylated B-Myb to stimulate transcription rather than a failure to form a complex with CBP. It is notable that B-Myb+561 was able to bind to CBP (Figure 8 ), despite the lack of synergism in transactivation assays (Figure 7a ).
Discussion
In common with c-Myb and A-Myb Takahashi et al., 1995; , the B-Myb C-terminus negatively in¯uences transactivation and DNA-binding activities. Inhibition of B-Myb and A-Myb DNA-binding is particularly in¯uenced by the C-terminal domain, and under standard EMSA conditions no binding to a single MBS can be detected with these full-length proteins (Takahashi et al., 1995; Watson et al., 1993) . We show here that removal of the 143 C-terminal aa of B-Myb (as in B-Myb+561) leads to a substantial increase in DNA binding anity (Figure 3 ). While these ®ndings suggest that a C-terminal domain acts negatively to regulate DNA-binding function, our results suggest surprisingly that phosphorylation does not relieve this inhibitory eect.
Analysis of a systematic set of C-terminally deleted Xenopus B-Myb mutants suggested that a DNAbinding regulatory domain (DBRD) located between aa 425 ± 458 controlled this activity (Humbert-Lan and Pieler, 1999) . The DBRD corresponds to aa 469 ± 502 in mouse B-Myb; this sequence constitutes the start of the CR and is very highly conserved between these species (30 of 34 aa are identical). It was suggested that the DBRD participates in intramolecular folding that masks DNA-binding activity, however, it is striking that DNA-binding activity could be unmasked in mouse B-Myb by removal of considerably fewer C- Whole cell extracts were then prepared; 5% was retained to measure the B-Myb protein input, while the remainder was divided in two and immunoprecipitated with either a CBP monoclonal antibody or a control antibody of the same immunoglobulin isotype (Con Ab). The retained input samples and the immunoprecipitates were Western blotted and probed for B-Myb proteins terminal residues than was observed in the Xenopus protein. This disparity suggests that there is actually no simple domain that regulates DNA-binding, rather this activity is uncovered when deletions of the protein are sucient to disrupt an autoinhibitory conformation.
Although 12 cyclin A/Cdk2 phosphorylation sites have now been identi®ed in B-Myb (Bartsch et al., 1999; Johnson et al., 1999; Saville and Watson, 1998 ), neither our current study nor previous work has identi®ed a particular site which is mandatory for regulation of B-Myb activity. It is likely, therefore, that phosphorylation at multiple sites leads to enhancement of B-Myb transactivation function. Serine 581 has consistently been identi®ed as a major cyclin A/Cdk2 phosphorylation site (Bartsch et al., 1999; Johnson et al., 1999; Saville and Watson, 1998) , although this site can apparently also be modi®ed by an unrelated kinase(s) as it remains phosphorylated in cells expressing Cdk2DN (Saville and Watson, 1998) , and it is of interest that truncation from +590 to +561 substantially increased DNA binding anity (Figure 3 ). Although these ®ndings are consistent with Ser581 regulating this activity, we found that cyclin A did not induce high anity DNA-binding in B-Myb+590 ( Figure 5 ). Paradoxically, it was found that an alanine mutation at B-Myb Ser581 increased DNA binding threefold in an assay using immobilized biotinylated oligonucleotides (Johnson et al., 1999) , suggesting that phosphorylation at this site actually inhibits B-Myb DNA-binding. B-Myb Ser581 corresponds to a c-Myb MAP kinase phosphorylation site (Ser528 in mouse cMyb) postulated to regulate interactions with other proteins (Miglarese et al., 1996; Vorbrueggen et al., 1996) ; mutation of c-Myb Ser528 was not found to aect DNA binding (Miglarese et al., 1996) . It may be suggested from our results (Figure 3a ) that mutation of B-Myb Ser581 partially disrupts an autoregulatory conformation, and it is this eect rather than abrogation of phosphorylation that resulted in increased DNA-binding activity (Johnson et al., 1999) .
It is apparent from the current results (Figure 3 ) that the CR is not essential for transactivation activity as was previously suggested by other ®ndings including our own (Nakagoshi et al., 1993; Lane et al., 1997) . It may be pertinent that in the mutants analysed by Nakagoshi et al. (1993) , and unexpectedly in pSVBmyb.Sca generated in our own laboratory, additional C-terminal aa were speci®ed by the modi®ed B-Myb gene from an out-of-frame coding sequence, and this may have abolished the activities of the mutant proteins. It is notable that an interstitial deletion of the CR also severely aected transactivation activity (Tashiro et al., 1995) , suggesting that in its absence the inhibitory conformation dictated by the B-Myb Cterminus can not be reversed. It will be of further interest to examine whether phosphorylation is able to activate CR mutants.
We found in this study that wt B-Myb synergized with CBP to activate the pT81luc 36A reporter (Figure 6 ), albeit B-Myb was less responsive to CBP than c-Myb. It is now apparent that c-Myb interacts with two distinct regions of CBP: the N-terminal KIX CREB-binding domain and a cysteine-histidine-rich region (C/H2) which lies within the histone acetyltransferase (HAT) domain (Sano and Ishii, 2001 ). The KIX domain interacts directly with the c-Myb transactivation domain, whilst the C/H2 region binds the c-Myb negative regulatory domain (NRD; within which lies the CR). CBP has been found to acetylate the c-Myb NRD at ®ve lysines (Tomita et al., 2000; Sano and Ishii, 2001) . As all of these residues are conserved in A-Myb and four are conserved in the BMyb CR, it may be suggested that the mechanism of CBP co-activation is similar between the members of the Myb family. Although the precise domains required for CBP/Myb interactions have yet to be de®ned, we have found that B-Myb interacts with an N-terminal CBP sequence (aa 1 ± 1099) which contains the KIX domain. KIX interacts with the c-Myb transactivation domain, and it is of interest to note that the equivalent B-Myb sequence diers markedly.
We found that transfection of Cdk2DN abrogated the response of B-Myb to CBP, whereas in contrast transfection of cyclin A facilitated this synergism. As B-Myb+561 activity was unaected by co-transfected CBP, the functional interactions of the wt and mutant B-Myb proteins appeared to parallel their responses to cyclin A/Cdk2 activity. Despite this, B-Myb phosphorylation did not aect binding to CBP (Figure 8 ). These observations are consistent with a model whereby interaction with CBP facilitates activating modi®ca-tions of B-Myb which overcome the C-terminal inhibitory domain. Although B-Myb appears to be a target for CBP acetylase activity (cited in Sano and Ishii, 2001) , the fact that Cdk2DN eliminated any synergy (Figure 7 ) suggests that CBP binding may instead facilitate B-Myb phosphorylation by cyclin A/ Cdk2. Although CBP binding is unaected by B-Myb phosphorylation, a recent report indicates that poly (ADP-ribose) polymerase (PARP) is also a B-Myb coactivator (Cervellera and Sala, 2000) , and it will be of interest to test whether phosphorylation aects this interaction.
It has recently been reported that B-Myb is subject to proteolysis by the ubiquitin/proteasome pathway (Charrasse et al., 2000) . Signi®cantly, destabilization of B-Myb in cyclin A co-transfected cells was accompanied by increased ubiquitination of B-Myb, while in contrast increased stability of a C-terminally truncated B-Myb protein (comprising aa 1 ± 508) was associated with reduced ubiquitination (Charrasse et al., 2000) . These ®ndings presumably account for our observation that B-Myb is stabilized in cells co-transfected with low inputs of Cdk2DN plasmids (Figure 1) .
Although there is a consensus that the B-Myb Cterminus contains a negative-regulatory domain whose inhibitory function can be overcome by cyclin Amediated phosphorylation (Ansieau et al., 1997; Johnson et al., 1999; Lane et al., 1997; Sala et al., 1997; , we have shown here that any conformational changes resulting from this modi®cation do not profoundly aect interactions with either DNA or CBP. Previous studies have shown that the nuclear location of B-Myb does not change during the cell cycle (Robinson et al., 1996) nor is it aected by cyclin A expression (Charrasse et al., 2000) , and to date the only property of hyperphosphorylated B-Myb that correlates with enhanced transactivation activity is protein instability. These ®ndings raise the possibility that cyclin A/Cdk2 modi®cation precipitates the generation of unstable, activated forms of B-Myb in which the autoinhibitory C-terminus has been removed. In support of this argument, it is clear that discrete truncated B-Myb forms, which are predicted to be highly transcriptionally active, can readily be generated (Figure 3 ), albeit we cannot exclude the possibility that these species were produced in vitro (despite the constant presence of protease inhibitors). On the other hand, neither EMSA nor Western blot data gave any indication that the abundance of these truncated species is increased upon B-Myb phosphorylation (Figure 3 ). While the generation of transiently active truncated B-Myb species in response to cyclin Amediated phosphorylation would clearly provide a rationale for the presence of an inhibitory C-terminal domain, it also remains possible that B-Myb hyperphosphorylation aects interactions with as yet unrecognized regulatory proteins. In this regard, several B-Myb-binding proteins have now been identi®ed which inhibit its transactivation function, for example p107, Cdk9 and cyclin D1 (Sala et al., 1996; De Falco et al., 2000; Horstmann et al., 2000) , and it will be of further interest to determine whether phosphorylation counteracts these eects.
Materials and methods
Plasmids
The pT81luc 36A reporter containing three MBS (the mim-1 A site) upstream of a minimal herpes simplex virus thymidine kinase promoter has been described previously (Ness et al., 1989) , as has pcDNA3/B-myb (Saville and Watson, 1998) . Plasmids encoding human cyclin A and Cdk2DN under control of the HCMV immediate early promoter were obtained from Phil Hinds and Ed Harlow as detailed (Saville and Watson, 1998) . A plasmid expressing full-length mouse CBP (pRc/RSV-mCBP.HA.RK) was obtained from Roland Kwok. To create the B-Myb deletion series, a universal translation terminator (a double-stranded oligonucleotide of sequence, CTAGTTAACTAG) was ®rst inserted into the EcoRV site of pcDNA3 to generate pcDNA3ter. The pSVBmyb plasmid encoding mouse B-Myb (Lane et al., 1997) was cut at an EcoRI site downstream of the insert, then 2 mg amounts were taken up in 50 ml BAL-31 endonuclease buer (New England Biolabs) and incubated with 1U BAL-31 at 308C for 10, 20, 30 or 40 min. Two further aliquots were incubated under the same conditions with 2U and 4U BAL-31 for 30 min. On completion of endonuclease digestion, the samples were diluted to 200 ml and made 5 mM EGTA. Following inactivation of BAL-31 by heating at 708C for 10 min, the DNA samples were ethanol precipitated and cut at a Hind III site upstream of the B-Myb cDNA. C-terminally truncated B-Myb cDNA sequences of the desired sizes were recovered from agarose gels and ligated into pcDNA3ter cut with EcoRI (end-®lled using the Klenow fragment) and Hind III. The B-Myb cDNA endpoints were determined by DNA sequencing.
Cell culture and transfection
The human osteosarcoma cell lines U-2 OS and Saos-2 were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% foetal calf serum. Cells were plated at 60% con¯uence and transfected using the calcium phosphate precipitation technique as described previously (Lane et al., 1997) . The precipitate was left overnight on U-2 OS cells but was washed o the Saos-2 cells after 8 h.
Electrophoretic mobility shift assay
To make freeze-thaw extracts for EMSA, 100 mm dishes of U-2 OS cells were transfected with 5 mg pT81luc 36A, 10 mg pcDNA3/B-myb or the truncated derivatives, 5 mg pCMVcycA or 5 mg pCMVCdk2DN as appropriate. The transfection mixes each contained 2 mg pSVûgal and a total DNA content of 30 mg, made up using the empty vectors as appropriate and pUC18. Extracts were made 2 days after transfection. The cells were ®rst washed twice with PBS, then recovered by scraping into PBS and centrifuging at low speed. Cell pellets were resuspended in 56EMSA buer, consisting of 500 mM NaCl, 100 mM HEPES, pH 7.4, 5 mM MgCl 2 , 5 mM NaF, 0.5 mM EDTA, 35% glycerol and the recommended concentration of a protease inhibitor cocktail (EDTA-free, Roche). After thorough freezing at 7708C, the lysed cells were thawed and incubated on ice for 30 min, then cellular debris was removed by centrifugation at 100 000 g for 30 min. DNA-binding assays were performed in a 20 ml volume of 16EMSA buer supplemented with 1 mM DTT, 1 mM PMSF, 0.5 mg denatured salmon sperm DNA, 1 mg poly(dI/dC), and 5 mg BSA using 10 mg cell extract. Initial EMSA contained 0.2 ng of a double-stranded mim-1 A site oligonucleotide (GCGCTAAAAAACCGTTATAATGC), 32 P-labelled by ®ll-in with Klenow polymerase. To make the 36A site DNA fragment probe, pT81luc 36A was cut with SalI/EcoRI and the 120 bp fragment was isolated from a polyacrylamide gel and labelled using polynucleotide kinase with 32 P-gATP. Approximately 1 ng of the probe was used in EMSA.
Promoter reporter assay
Luciferase and b-galactosidase assays were performed as described previously on 2 ml of the freeze-thaw extracts used in EMSA. So that direct comparisons could be made with the EMSA results, luciferase values were adjusted according to the protein content of the cell extract rather than the û-galactosidase values. Standard reporter assays were done following transfection into cells plated on 60 mm dishes as described (Lane et al., 1997) . Extracts for Western blots were made simultaneously from cells transfected in parallel.
Western blot and immunoprecipitation analyses
For Western blot analysis, cells were either washed twice with PBS and then lysed directly in electrophoresis sample buer (50 mM Tris pH 6.8, 2% SDS, 10% glycerol, 10 mM EDTA, 0.007% bromophenol blue) or freeze-thaw lysates were diluted in 26 sample buer. After sonication samples were stored at 7708C. The protein concentrations of SDS sample Regulation of B-Myb transactivation function M Bessa et al buer extracts were measured using the BCA protein assay (Pierce). After addition of DTT to a ®nal concentration of 100 mM, equal amounts of protein (20 ± 40 mg) were analysed by Western blotting with a polyclonal antibody raised against the N-terminal 19 aa of B-Myb (Santa Cruz sc-724). For CBP immunoprecipitation studies, 100 mm dishes of U-2 OS cells were ®rst transfected with 10 mg pRc/ RSVmCBP.HA.RK together, as appropriate, with 10 mg pcDNA3/B-myb, pcDNA3/B-myb+561 or the empty pcDNA3 vector, 3 mg pCMV.cycA or 1.5 mg pCMV.cdk2DN. Two days later, the cells were lysed with 2 ml lysis buer (50 mM HEPES, pH 7.5, 220 mM NaCl, 0.5% NP40, 5 mM EDTA, 10 mM NaF, 10 mM sodium pyrophosphate, 10 mM û-glycerophosphate, 2 mM Na 3 VO 4 , 5 mM benzamidine, 1 mM dithiothreitol, containing the recommended concentration of a protease inhibitor cocktail [Roche] ). Five per cent of each lysate was retained and added to 26SDS sample buer (input), while the remainder was split into two. The CBP monoclonal antibody AC238 (a gift from Richard Eckner) was added to one aliquot while the other received an irrelevant IgG1 monoclonal antibody. After incubation on ice for 2 h, rabbit anti-mouse IgG1 antibody was added for a further 1 h before the immune complexes were collected on protein A sepharose beads. The beads were recovered by low speed centrifugation and washed three times with lysis buer prior to eluting the bound proteins by boiling in SDS sample buer. The eluted proteins were analysed by Western blotting as above.
